Drug giant Roche to offer clinical services
19 January, 2006 by Ruth BeranIn what it believes is an industry first, Roche Pharmaceuticals will offer its clinical development services to outside customers, particularly non-government organisations (NGOs), according to the drug giant's global head of clinical pharmacology development, Prof Graham McClelland.
Norwood in bid to buy Dutch vaccine firm
19 January, 2006 by Helen SchullerImmune therapy developer and Norwood Abbey (ASX:NAL) subsidiary Norwood Immunology (AIM:NIM) has entered into an option to acquire all the share capital of Netherlands-based Bestewil Holding, the 100 per cent owner of Virosome Biologicals Group, for up to 25 million euros (AUD$40.5 million).
Triple whammy may inhibit Tamiflu as bird flu weapon
17 January, 2006 by Graeme O'NeillThe failure of the anti-influenza drug Tamiflu to save the lives of patients with established H5N1 avian influenza infections may be a consequence of the drug's design, mode of delivery, and the uniqueness of the virus itself, according to experts.
FDA wants more data before approving C3's ReCell
16 January, 2006 by Ruth BeranTissue engineering specialist Clinical Cell Culture's (ASX:CCE, C3) share price took a blow today, in the wake of a request by the US Food and Drug Administration (FDA) for more performance data before it can approve C3's ReCell for sale in the US.
EvoGenix touts positive bone treatment results
16 January, 2006 by Helen SchullerEvoGenix (ASX:EGX) has reported results on the development of its product OVP, for the treatment of bone loss.
BioPharmica aims to raise $2.5m
13 January, 2006 by Helen SchullerPerth based BioPharmica (ASX:BPH) has opened a share purchase plan to raise AUD$2.5 million to fund the development of its portfolio of biomedical research.
Antisense to resume MS phase IIa trial
12 January, 2006 by Helen SchullerMelbourne's Antisense Therapeutics (ASX:ANP) has been granted approval to restart the phase IIa trial of its antisense compound ATL1102 for patients with relapsing remitting multiple sclerosis.
LCT raises $3m from mainly US investors
12 January, 2006 by Ruth BeranCell therapy company Living Cell Technologies (ASX:LCT) has raised more than AUD$3 million through a placement of ordinary shares to US shareholders and an Australian investor.
Narhex commences phase I HIV drug trial
11 January, 2006 by Helen SchullerAnti-viral drug developer Narhex Life Sciences (ASX:NLS) has commenced recruitment of healthy volunteers for the phase I clinical trial of its anti-HIV protease inhibitor drug DG17.
HeartWare gets Austrian thumbs-up
11 January, 2006 by Helen SchullerArtificial heart firm HeartWare (ASX:HTW) has been granted its first regulatory approval to commence human implants of the HVAD left ventricular assist device from the Austrian Ministry of Health.
GroPep goes into phase I infertility trial
10 January, 2006 by Helen SchullerGroPep (ASX:GRO) has begun to recruit healthy women volunteers into a phase I trial of its infertility drug PV903, targeted to treat recurrent miscarriages caused by an abnormal immune response to the foetus.
Bio-Layer in new US development deal
10 January, 2006 by Helen SchullerBrisbane based Bio-Layer, a wholly-owned subsidiary of SSH Medical (ASX:SSH), has entered into a development and marketing agreement with a US-based life sciences company for the use of its surface coating product Mix&Go.
Epitan reveals milestones for $10m VC funding
09 January, 2006 by Ruth BeranMelbourne-based Epitan (ASX:EPT, ADR:EPTNY, XETRA:UR9) has entered into a funding agreement with international specialist fund Absolute Capital Management (ACM) to raise AUD$10 million over the next 18 months.
Psiron's Cavatak recevies FDA orphan drug designation
21 December, 2005 by Ruth BeranSydney oncology therapy developer Psiron (ASX:PSX) has received orphan drug designation from the US Food and Drug Administration (FDA) for its lead oncolytic virus Cavatak (coxsackievirus A21) for the treatment of stage II, stage III and stage IV melanoma.
Cryptome, HealthLinx formalise merger plans
21 December, 2005 by Ruth BeranThe merger between Melbourne-based companies Cryptome Pharmaceuticals (ASC:CRP) and diagnostics developer HealthLinx has been formalised, following the firms entering a non-binding terms sheet in November.
